Actively Recruiting
Memory Enhancement Using Transcranial Alternating Current Stimulation
Led by Amsterdam UMC, location VUmc · Updated on 2024-12-20
27
Participants Needed
1
Research Sites
63 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI) to AD are therefore of high priority. Transcranial alternating current stimulation (tACS) is a safe and patient-friendly non-invasive brain stimulation technique that serves as a potential candidate for reducing and/or slowing cognitive impairment. Application of tACS in the gamma frequency range, specifically around 40 Hz, has been studied in patients with AD and MCI due to AD. In these patients, a single session of 40 Hz tACS at the precuneus showed to improve episodic memory and to increase gamma power, as measured with electroencephalography. These findings will be replicated in the current study in patients with MCI due to AD, using magnetoencephalography (MEG) recorded before, during and after tACS. In this way, brain activity and network changes that underlie this improvement in episodic memory can be studied with greater temporal and spatial detail.
CONDITIONS
Official Title
Memory Enhancement Using Transcranial Alternating Current Stimulation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Recent (not more than 6 months ago) amnestic MCI diagnosis confirmed by a multidisciplinary memory clinic evaluation
- Confirmation of Alzheimer's disease pathology with cerebrospinal fluid biomarkers showing abnormal p-tau/A2 ratio of > 0.023
You will not qualify if you...
- Serious neurological, psychiatric, or physical comorbidities
- History of epileptic seizures or severe claustrophobia
- Intensive use of psychoactive medication
- Presence of cardiac pacemaker, internal cardiac defibrillator, or other intracorporeal devices interfering with MEG recordings
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Amsterdam UMC, The Netherlands
Amsterdam, North Holland, Netherlands, 1081HV
Actively Recruiting
Research Team
W
Willem de Haan, dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here